How Dietary Supplements Are Regulated in the U.S.

Dietary supplements — including protein powders, amino acids, vitamins, minerals, and herbal extracts — occupy a legal category that sits between conventional food and prescription drugs. That category was formally defined by the Dietary Supplement Health and Education Act of 1994, commonly called DSHEA, and the rules it established still govern what can be sold, what can be claimed, and who is responsible for what.

The question of whether dietary supplements are regulated by the FDA does not have a simple yes-or-no answer. The FDA does regulate the category, but the nature of that oversight differs substantially from the pre-market approval process that applies to pharmaceutical drugs. Understanding the structure of that difference is the starting point for reading any supplement label accurately.

How DSHEA Defines the Regulatory Framework for Dietary Supplements

Under DSHEA, a dietary supplement is defined as a product intended to supplement the diet that contains a dietary ingredient — such as a vitamin, mineral, herb, amino acid, or concentrate thereof. The law places the burden of demonstrating safety on the manufacturer, not on the FDA. Before a new dietary ingredient (NDI) introduced after October 15, 1994 is marketed, the manufacturer is required to notify the FDA at least 75 days in advance and provide evidence that the ingredient is reasonably expected to be safe. For ingredients already in use before that date, no such notification is required.

The FDA does not evaluate or approve dietary supplement products before they are placed on the market. This is the core structural difference between supplement regulation and drug regulation. A pharmaceutical drug must pass through clinical trials and receive explicit FDA approval before sale. A dietary supplement may be sold as soon as the manufacturer determines it meets the legal definition and safety standard, provided it does not make a disease claim.

Once a product is on the market, the FDA's authority shifts to post-market surveillance. The agency monitors adverse event reports, can issue warning letters, and has the power to remove a product it determines to be unsafe or misbranded. The Federal Trade Commission (FTC) holds parallel authority over advertising claims — meaning a supplement's marketing language faces FTC scrutiny even when its label is under FDA jurisdiction.

Current Good Manufacturing Practice (cGMP) regulations, finalized in 2007, require supplement manufacturers to follow documented quality-control procedures covering identity, purity, strength, and composition of their products. These rules require that what is on the label is actually in the bottle, and that the product is free from contaminants. The FDA can inspect manufacturing facilities and take enforcement action when cGMP violations are found, but the agency does not routinely test products before they ship.

The Agencies, Bodies, and Legal Instruments Involved in Supplement Oversight

The FDA (Food and Drug Administration) is the primary federal body governing dietary supplement safety, labeling, and manufacturing standards. It enforces DSHEA, the cGMP regulations, and the NDI notification process. It does not pre-approve products but can act against those that are unsafe, adulterated, or misbranded after they reach the market. For a fuller look at how this authority is structured, the framework governing the supplement industry involves several overlapping layers of federal oversight.

The FTC (Federal Trade Commission) governs advertising and marketing claims for dietary supplements. Under FTC standards, any claim made in advertising must be substantiated by competent and reliable scientific evidence. The FTC has brought enforcement actions against companies making unsubstantiated health claims in digital and broadcast advertising, even when the FDA had not yet acted on the same product's label.

Manufacturers and distributors carry the primary legal responsibility under DSHEA for ensuring that their products are safe before marketing. They are required to maintain records, follow cGMP procedures, and report serious adverse events to the FDA within 15 business days under the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006.

Third-party testing organizations are private entities — not government agencies — that offer voluntary certification programs. They test products for label accuracy, contaminant levels, and manufacturing consistency. A seal from one of these organizations on a label indicates the product passed that organization's specific testing protocol; it does not indicate FDA review or approval. How that testing process actually functions is covered in detail in the article on how third-party supplement testing actually works.

Structure/function claims are the specific type of claim DSHEA permits on supplement labels. A manufacturer may state that a nutrient "supports immune function" or "helps maintain muscle mass," but may not claim the product "treats," "cures," or "prevents" any disease. Products carrying a structure/function claim must include a disclaimer stating the claim has not been evaluated by the FDA.

Where Supplement Regulation Produces Gaps and Misunderstandings

The most consequential gap in the current framework is the absence of pre-market product review. Because the FDA does not test or approve supplements before sale, products that are adulterated, mislabeled, or contaminated can reach consumers before any regulatory action occurs. The agency's enforcement capacity is reactive rather than preventive for the vast majority of products.

The NDI notification process, which was designed to catch potentially unsafe novel ingredients, has been inconsistently applied. Some manufacturers have introduced ingredients without submitting the required notification, and the FDA's capacity to identify and challenge all such cases is limited by both resources and the sheer volume of products in the market.

Label accuracy under cGMP is a documented area of inconsistency. Independent testing has repeatedly found that the quantity of a declared ingredient — including protein content in protein supplements — does not always match the label claim. This gap exists not because cGMP permits it, but because enforcement depends on inspection and testing that does not cover every product. The process by which protein is isolated and concentrated, for example, creates multiple points where yield and composition can vary; how whey isolate is made from milk illustrates how many processing steps precede the final label declaration.

Structure/function claims are another source of consumer misunderstanding. The legal boundary between a permitted structure/function claim and a prohibited disease claim is not always obvious to a general reader. A claim that a product "supports healthy blood sugar levels already within a normal range" is structured to avoid a disease claim, but readers may interpret it as a therapeutic statement. The required disclaimer — that the FDA has not evaluated the claim — appears in small type and is frequently overlooked.

Third-party seals are sometimes conflated with government approval. A certification logo on a label is a private quality attestation, not an FDA endorsement. The scope of what any given seal covers — identity testing only, contaminant screening, full cGMP audit — varies by organization and program, and is not standardized across the industry.

What a Supplement Label and Certification Actually Document Under This Framework

A dietary supplement label is required by law to include a Supplement Facts panel listing serving size, declared ingredients and their amounts, and the percent Daily Value where applicable. It must include the manufacturer's name and address, a statement of identity, and net quantity. If a structure/function claim is present, the FDA disclaimer must also appear.

What the label does not document is independent verification of those declarations. The amounts listed reflect the manufacturer's own testing and formulation records. Whether those amounts are accurate at the time of manufacture, and whether they remain stable through the product's shelf life, is not confirmed by the label itself.

A third-party certification seal, when present, documents that an independent organization tested a sample of the product and found it consistent with the label claim within that organization's tolerances. It also typically documents that the tested sample fell below specified thresholds for contaminants such as heavy metals, pesticides, or undeclared substances. What it does not document is ongoing batch-level consistency — certification is typically based on periodic testing, not continuous production monitoring.

The FDA's cGMP compliance status of a manufacturer is a matter of inspection record, not label disclosure. A product's label does not indicate whether the facility that made it has passed a recent FDA cGMP inspection, received a warning letter, or never been inspected. Consumers and retailers do not have a standardized mechanism to access that information from the label alone. The broader question of whether supplements are regulated by the FDA is one that the label itself answers only partially and indirectly.

The regulatory structure for dietary supplements reflects a deliberate legislative choice made in 1994 to treat supplements differently from drugs — placing primary responsibility on manufacturers and reserving government intervention largely for post-market enforcement. That structure has remained substantially intact for three decades, and the gap between what a label asserts and what independent evidence confirms remains one of the defining features of the category.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.